Year 2 on GLP-1

The two-year mark is where the GLP-1 conversation gets quieter — and where the long-term evidence becomes more interesting. The pivotal trials measured year one; the extensions measured year two. What they showed is reassuring on safety and persistence of effect, but it also reframes the medication from a weight-loss tool into a chronic-disease treatment.

Most users entering year two have already settled into a routine. The injections are a Sunday habit. The food noise is quiet. The weekly scale changes are small. The big questions are no longer about titration or side effects — they are about cost, dose, long-term plans, and how to think about the medication five, ten, or twenty years out.

This guide walks through what the year-two data shows, what changes practically between year one and year two, and what the decisions at the two-year mark typically look like.

What the research shows

The STEP 5 trial extended STEP 1 out to two years. At week 104, users who continued semaglutide 2.4 mg held mean weight loss of approximately 15.2% from baseline, compared with 2.6% on placebo. That is essentially the same magnitude as week 68 — small additional loss between months 12 and 24, with most users settling into a stable maintenance band. The clinical takeaway: continued treatment sustains the result. Stopping, per STEP 4, undoes most of it within a year.

Safety at two years remained consistent with year one. Gastrointestinal adverse events were the dominant category, mostly mild to moderate, and rates declined from titration into the maintenance phase. There was no signal of new severe events emerging specifically in year two. The cardiovascular outcomes data from SELECT (which followed users on semaglutide 2.4 mg with established cardiovascular disease) further supported long-term safety and showed a 20% reduction in major adverse cardiovascular events over a median follow-up of more than three years.

Tirzepatide's long-term picture is similar in shape. SURMOUNT-4, the maintenance trial, showed that continued tirzepatide held the loss while placebo regained roughly half. Two-year head-to-head data between semaglutide and tirzepatide on weight-loss endpoints is still emerging, but the pattern across both molecules is the same: persistence of effect with continued use, regain after discontinuation, and an acceptable long-term safety profile in the populations studied.

What this looks like day-to-day

Year two is structurally calmer than year one. The dramatic part of the journey — titration, side effects, rapid loss, the psychological adjustment to a new body — is mostly behind. What replaces it is a maintenance routine that runs largely on autopilot. Many users describe year two as the easiest part of treatment because the active work is finished and the medication is doing background work.

The dose question becomes more individual in year two. Some users stay at their year-one maximum dose. Others step down — semaglutide users to 1.0 or 1.7 mg, tirzepatide users to 10 mg — because the lower dose holds the loss adequately and saves money or reduces residual side effects. A minority try treatment breaks or alternate dosing schedules; these are off-label and individual, and the data on them is thinner.

The cost conversation becomes more pointed in year two. The medication is expensive, insurance coverage varies, and the prospect of paying out of pocket indefinitely is a real consideration for many users. This is the year where the chronic-disease framing of obesity is most visible: like blood pressure or cholesterol medication, GLP-1 maintenance is an ongoing cost, not a finite one. Some users address this with compounded alternatives where available; others negotiate maintenance dose changes; others accept the cost as a fixed expense.

Common questions

Keep exploring

Browse all GLP-1 guides.